
    
      Bicentric, randomized, double-blind controlled study Outpatients aged from 18 to 60 years,
      suffering from current idiopathic hypersomnia (ICSD-3), recruited via medical consultations
      in the investigation centers Randomization in Xyrem or placebo arms after the inclusion
      visit,

      1.Screening Period (up to 15 days), 2.Titration Period (up to 45 days), 3.Maintenance Period
      (minimum 15 days), 4.Safety Follow-Up Period (14 days)
    
  